Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1Diabetes Mellitus 1

Interventions

Nutrition Assessment 3Metformin 3Tablets 2Resistance Training 2Pioglitazone 2Methods 2Exercise 2Educational Status 2otelixizumab 1nabiximols 1Verapamil 1Therapeutics 1Surveys and Questionnaires 1Specimen Handling 1Risk Assessment 1Remote Consultation 1Pancreas, Artificial 1Palliative Care 1Lysine Acetyltransferase 5 1Jogging 1Interviews as Topic 1Gastrectomy 1Fish Oils 1Endoscopic Mucosal Resection 1Eating 1Docosahexaenoic Acids 1Diet, Mediterranean 1Diet, Fat-Restricted 1Diet, Carbohydrate-Restricted 1DM199 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diabetes Mellitus × Becaplermin × Clear all
NCT00518102 2016-07-19

The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

Ethicon, Inc.

Completed
4,431 enrolled

Diabetes Mellitus, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡